SECsense Logo

Tonix Pharmaceuticals 8-K Report: Key Updates as of December 20, 2024

$TNXP
Form 8-K
Filed on: 2024-12-20
Source
Tonix Pharmaceuticals 8-K Report: Key Updates as of December 20, 2024

Based on the provided excerpt from the financial report, here are the key pieces of information extracted:

  1. Entity Identification:
  • Company Name: Tonix Pharmaceuticals Holding Corp.
  • CIK (Central Index Key): 0001430306
  • NASDAQ Ticker Symbol: TNXP
  • IRS Employer Identification Number: 26-1434750
  • Address: 26 Main Street, Chatham, NJ 07928
  • Contact Number: 862-904-8182
  1. Filing Details:
  • Filing Type: 8-K (Current Report)
  • Filing Date: December 20, 2024
  1. Context and Reporting Period:
  • Reporting Date: As of December 20, 2024
  • Period Start Date: December 20, 2024
  • Period End Date: December 20, 2024
  1. Financial Units:
  • Currency: USD (United States Dollar)
  • Measure Units: Shares and USD per Share (USDPShares)
  1. Schema Reference:
  • Schema File: tnxp-20241220.xsd

Insights:

  • The report is an 8-K filing, which typically indicates that the company is reporting significant events or changes that shareholders should be aware of. This could include various corporate changes, financial results, or other important announcements.
  • The reporting date and period coincide, which suggests that this filing may contain information about a specific event or change occurring on that exact date.
  • The mention of shares indicates that the report likely includes information pertinent to the company's stock performance or shareholder actions, which could be of interest to investors.

Overall, this document serves as a formal notification to investors and stakeholders about significant developments within Tonix Pharmaceuticals as of the specified date. Further details would be needed to understand the specific contents and implications of the 8-K filing.